Twist Bioscience Co. (NASDAQ:TWST) Receives $54.40 Average PT from Brokerages

Twist Bioscience Co. (NASDAQ:TWST) has been given a consensus recommendation of “Moderate Buy” by the ten analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $54.40.

TWST has been the topic of several research analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research note on Tuesday, February 4th. Wolfe Research initiated coverage on Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Robert W. Baird increased their target price on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. Finally, Barclays set a $58.00 target price on Twist Bioscience and gave the company an “overweight” rating in a research note on Monday, February 3rd.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $41.88 on Monday. The business has a 50 day simple moving average of $45.38 and a 200 day simple moving average of $45.34. Twist Bioscience has a one year low of $27.41 and a one year high of $60.90. The company has a market capitalization of $2.50 billion, a PE ratio of -12.39 and a beta of 2.15. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm’s revenue for the quarter was up 24.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.75) EPS. On average, sell-side analysts forecast that Twist Bioscience will post -2.12 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Robert Chess sold 2,940 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $53.13, for a total value of $156,202.20. Following the transaction, the director now owns 18,173 shares of the company’s stock, valued at $965,531.49. This represents a 13.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Dennis Cho sold 806 shares of Twist Bioscience stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $39,776.10. Following the sale, the insider now directly owns 112,221 shares of the company’s stock, valued at approximately $5,538,106.35. This trade represents a 0.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,799 shares of company stock worth $1,593,944 over the last three months. 3.01% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds have recently added to or reduced their stakes in TWST. Intech Investment Management LLC bought a new stake in shares of Twist Bioscience in the 3rd quarter valued at about $714,000. Massachusetts Financial Services Co. MA grew its holdings in Twist Bioscience by 215.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock valued at $1,324,000 after purchasing an additional 20,035 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Twist Bioscience by 4.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 524,942 shares of the company’s stock valued at $23,717,000 after purchasing an additional 24,582 shares in the last quarter. Algert Global LLC raised its holdings in Twist Bioscience by 59.7% in the third quarter. Algert Global LLC now owns 43,592 shares of the company’s stock worth $1,969,000 after purchasing an additional 16,292 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Twist Bioscience in the third quarter worth $599,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.